Fauzee Nilufer Jasmine Selimah
Department of Pathology, Molecular Medicine and Cancer Research Center, Chongqing, China.
Asian Pac J Cancer Prev. 2011;12(4):837-51.
Taxanes are amongst the most promising antitumor agents available at hand today, of increasing importance in Asia given that cancer is now one of the major public health problems which needs to be dealt urgently for the benefit of affected patients. Several ongoing experimental and clinical trials have supported the fact that even with their side effects and poor solubilities, taxanes are still the first lines of treatment chosen for breast, ovary, lung and other metastatic cancers. Prolonging the life of cancer patients is the main aim of all researchers, scientists, pharmaceutical companies and clinicians; therefore this review emphasizes the mechanisms of action of taxanes and how they can play an important role in palliative treatment if not applied for curative purposes, hence being considered a boon for cancer management.
紫杉烷类是当今最有前景的抗肿瘤药物之一，鉴于癌症现已成为需要紧急应对以造福患者的主要公共卫生问题之一，在亚洲其重要性日益增加。几项正在进行的实验和临床试验都证实了，尽管紫杉烷类有副作用且溶解度不佳，但它们仍是乳腺癌、卵巢癌、肺癌和其他转移性癌症的首选一线治疗药物。延长癌症患者的生命是所有研究人员、科学家、制药公司和临床医生的主要目标；因此，本综述着重阐述了紫杉烷类的作用机制，以及如果不用于根治目的，它们如何能在姑息治疗中发挥重要作用，从而被视为癌症治疗的福音。
